Auriet: Obtained the registration approval for Enzalutamide tablets.

Aokete announced that it has recently received two Enzalutamide tablets "Drug Registration Certificates" approved and issued by the National Medical Products Administration, with specifications of 80mg and 40mg, for the treatment of various prostate cancers. Enzalutamide is a second-generation androgen receptor inhibitor. The original drug entered the Chinese market in 2019, but Enzalutamide tablets have not been marketed domestically. As of December 31, 2025, the company has invested approximately 20,301.3 yuan in the research and development of this drug. The market sales of the drug are influenced by various factors and have uncertainties.